Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Robert L. Ray who wrote (25808)	9/28/1998 2:45:00 PM
From: Henry Niman	Read Replies (2) \| Respond to of 32384

Actually, the side effect news isn't news, but the trial suspension and looking for SERM partner is. LGND has SERM partnerships with most major players (LLY, AHP, PFE) but doesn't have a SERM deal with SBH. I believe that SBH's Idoxifene is farthest along in clinical trials (except for Tamoxifen and Evista, which are already on the market).

To: Robert L. Ray who wrote (25808)	9/29/1998 2:30:00 AM
From: Cheryl Galt	Read Replies (2) \| Respond to of 32384

>> Novo Nordisk is getting hammered today >> on news that they are suspending clinicals on their SERM >> because of side effects What a lightweight hammer! tapping a big-cap pharma To all: What do you make of NVO's low volume ??? Monday's volume was ~8 times an average of squat 11,020 average volume 85,200 volume on 8/28 150,000,000 shares out ~8B market cap NVO closed at $60 9/16, down 13.94% on bad news LGND closed at $11.5 -----up 14.29% on no news 329,500 volume on 8/28 039,000,000 shares out ~.5B market cap NVO - quote.yahoo.com